2.61 USD
▲+0.01+0.38%
盘后 2.53 0.00%
2026-09-16
市值
$11.50M
市盈率
—
EPS
-2.30
股息率
—
52 周区间
1.77 – 2.95
成交量
24.83K
Beta
-0.33
目标价
—
52W 低 1.7752W 高 2.95
价格走势
公司简介
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the tre...